ResearcherAduro BioTech (United States)No recent work listed
Nitya Nair
Matched on ORCID iD 0000-0002-9524-9313; OpenAlex author ID A5062010822. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper
Papers 3
- Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-19-0650↗
- Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
- Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancrea… Co-author DOI 10.1186/2051-1426-3-s2-p102↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dung Thi Le · 3 shared papers, 2015–2020 · strength 0.23
- Paper Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Pat… DOI 10.1158/2326-6066.cir-19-0650↗
- Paper Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adul… DOI 10.1158/1078-0432.ccr-18-2992↗
- Paper Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunothe… DOI 10.1186/2051-1426-3-s2-p102↗
- Dirk G. Brockstedt · 3 shared papers, 2015–2020 · strength 0.23
- Paper Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Pat… DOI 10.1158/2326-6066.cir-19-0650↗
- Paper Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adul… DOI 10.1158/1078-0432.ccr-18-2992↗
- Paper Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunothe… DOI 10.1186/2051-1426-3-s2-p102↗
- Chan C. Whiting · 3 shared papers, 2015–2020 · strength 0.23
- Paper Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Pat… DOI 10.1158/2326-6066.cir-19-0650↗
- Paper Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adul… DOI 10.1158/1078-0432.ccr-18-2992↗
- Paper Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunothe… DOI 10.1186/2051-1426-3-s2-p102↗
- Elizabeth M. Jaffee · 3 shared papers, 2015–2020 · strength 0.23
- Paper Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Pat… DOI 10.1158/2326-6066.cir-19-0650↗
- Paper Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adul… DOI 10.1158/1078-0432.ccr-18-2992↗
- Paper Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunothe… DOI 10.1186/2051-1426-3-s2-p102↗
- Zev A. Wainberg · 1 shared paper, 2019 · strength 0.07
- Andrew H. Ko · 1 shared paper, 2019 · strength 0.07
- Dan A. Laheru · 1 shared paper, 2019 · strength 0.07
- Todd S. Crocenzi · 1 shared paper, 2019 · strength 0.07
- Noelle K. LoConte · 1 shared paper, 2019 · strength 0.07
- Herbert J. Zeh · 1 shared paper, 2019 · strength 0.07
- Michael Andrew Morse · 1 shared paper, 2019 · strength 0.07
- Hedy Lee Kindler · 1 shared paper, 2019 · strength 0.07
- Erkut Hasan Borazanci · 1 shared paper, 2019 · strength 0.07
- Andrea Wang‐Gillam · 1 shared paper, 2019 · strength 0.07
- Vincent J. Picozzi · 1 shared paper, 2019 · strength 0.07
- Benjamin Musher · 1 shared paper, 2019 · strength 0.07
- Colin D. Weekes · 1 shared paper, 2019 · strength 0.07
- Paul E. Oberstein · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.